Cocrystal Pharma's Investigational Drug Candidate CC-42344 Demonstrates Strong Antiviral Potency Against the 2024 Highly Pathogenic H5N1 Avian Influenza Strain

Stock Information for Cocrystal Pharma Inc.

Loading

Please wait while we load your information from QuoteMedia.

More Recent News About Cocrystal Pharma Inc.

Cocrystal Pharma's Novel Norovirus Antiviral to be Presented at Department of Defense Medical Conference
Cocrystal Pharma to Participate in Noble Capital Markets' 2025 Emerging Growth Virtual Equity Conference
Cocrystal Pharma Reports First Quarter 2025 Financial Results and Provides Updates on its Antiviral Drug-Development Programs
Cocrystal Pharma's Norovirus Oral Antiviral Candidate Demonstrates Potent Activity Against the Emerging GII.17 Variants
Cocrystal Pharma to Present at Life Science Innovation Northwest 2025 Conference
Cocrystal Pharma Reports 2024 Financial Results and Provides Updates on its Antiviral Drug-Development Programs
Life Science Virtual Investor Forum: Presentations Now Available for Online Viewing
Life Sciences Investor Forum Agenda Announced for March 13th

Market data content copyright © QuoteMedia. Data delayed at least 15 minutes unless otherwise indicated (view Delay Times for all exchanges). Filings and Fundamentals by Morningstar. Insiders by Morningstar (USA) and SEDI (CDN). Analyst ratings by Zacks. Terms of Use.